Total Payments
$6,995
2024 Payments
$771.17
Companies
41
Transactions
257
Medicare Patients
1,956
Medicare Billing
$434,687
Payment Breakdown by Category
Food & Beverage$6,357 (90.9%)
Education$638.89 (9.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,357 | 247 | 90.9% |
| Education | $638.89 | 10 | 9.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $925.62 | 52 | $0 (2024) |
| Amgen Inc. | $537.90 | 21 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $440.86 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $408.96 | 19 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $400.87 | 9 | $0 (2022) |
| Merck Sharp & Dohme LLC | $397.91 | 21 | $0 (2024) |
| Astellas Pharma US Inc | $355.60 | 7 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $345.16 | 5 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $329.36 | 17 | $0 (2023) |
| PFIZER INC. | $281.15 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $771.17 | 37 | Janssen Biotech, Inc. ($245.99) |
| 2023 | $553.85 | 31 | Janssen Biotech, Inc. ($205.42) |
| 2022 | $1,019 | 28 | AstraZeneca Pharmaceuticals LP ($250.00) |
| 2021 | $249.39 | 9 | Janssen Biotech, Inc. ($214.33) |
| 2020 | $110.40 | 1 | Novartis Pharmaceuticals Corporation ($110.40) |
| 2019 | $1,134 | 52 | Amgen Inc. ($150.96) |
| 2018 | $1,623 | 51 | Amgen Inc. ($367.84) |
| 2017 | $1,534 | 48 | Bayer HealthCare Pharmaceuticals Inc. ($281.86) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $8.34 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Rare Disease | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $0.97 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Hematology | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $10.40 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: Oncology | ||||||
| 06/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Oncology | ||||||
| 05/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.30 | General |
| 05/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 04/26/2024 | PFIZER INC. | — | Education | In-kind items and services | $99.95 | General |
| 04/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $108.64 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Oncology | ||||||
| 04/15/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: ONCOLOGY | ||||||
| 04/14/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $4.59 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Oncology | ||||||
| 03/27/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.01 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 441 | 992 | $209,272 | $101,385 |
| 2022 | 10 | 602 | 1,162 | $258,638 | $130,209 |
| 2021 | 8 | 524 | 1,075 | $216,223 | $126,244 |
| 2020 | 7 | 389 | 751 | $154,147 | $76,849 |
Total Patients
1,956
Total Services
3,980
Medicare Billing
$434,687
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 211 | 536 | $102,376 | $48,817 | 47.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 86 | 289 | $78,319 | $39,394 | 50.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 74 | 90 | $12,240 | $5,139 | 42.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 29 | $8,961 | $4,349 | 48.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 26 | 32 | $4,320 | $2,211 | 51.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 16 | $3,056 | $1,475 | 48.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 142 | 524 | $138,945 | $72,520 | 52.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 220 | 373 | $70,154 | $32,883 | 46.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $10,668 | $5,391 | 50.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $10,458 | $5,206 | 49.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 50 | 63 | $8,406 | $3,951 | 47.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $6,489 | $3,836 | 59.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 26 | 31 | $4,094 | $1,945 | 47.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 15 | 18 | $3,388 | $1,801 | 53.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 39 | 43 | $3,534 | $1,700 | 48.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 15 | 15 | $2,502 | $976.75 | 39.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 127 | 373 | $85,595 | $52,260 | 61.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 188 | 480 | $80,025 | $45,981 | 57.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 57 | 57 | $17,955 | $9,575 | 53.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 60 | 60 | $15,240 | $7,529 | 49.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 25 | 26 | $8,034 | $4,637 | 57.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 22 | 30 | $4,291 | $2,998 | 69.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 27 | 29 | $2,767 | $1,836 | 66.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 20 | $2,316 | $1,428 | 61.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 98 | 389 | $85,969 | $43,383 | 50.5% |
About Dr. Bachir Berbari, MD
Dr. Bachir Berbari, MD is a Hematology & Oncology healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2013. The National Provider Identifier (NPI) number assigned to this provider is 1407288996.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bachir Berbari, MD has received a total of $6,995 in payments from pharmaceutical and medical device companies, with $771.17 received in 2024. These payments were reported across 257 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($6,357).
As a Medicare-enrolled provider, Berbari has provided services to 1,956 Medicare beneficiaries, totaling 3,980 services with total Medicare billing of $434,687. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Boca Raton, FL
- Active Since 08/06/2013
- Last Updated 08/22/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1407288996
Products in Payments
- ERLEADA (Drug) $517.44
- KEYTRUDA (Biological) $397.91
- Stivarga (Drug) $386.23
- Imbruvica (Drug) $345.16
- DARZALEX (Biological) $291.53
- VENCLEXTA (Drug) $253.48
- ENHERTU (Biological) $250.00
- Kyprolis (Biological) $175.08
- Revlimid (Drug) $163.48
- KISQALI (Drug) $161.96
- Lenvima (Drug) $150.34
- NINLARO (Drug) $143.02
- CALQUENCE (Drug) $125.00
- Prolia (Biological) $125.00
- Avastin (Biological) $124.31
- VYXEOS (Drug) $117.01
- Onivyde (Drug) $114.51
- EMPLICITI (Biological) $113.38
- OPDIVO (Biological) $113.01
- Neulasta (Biological) $105.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boca Raton
Mohammad Jahanzeb, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Fernando Recio, Md, MD
Hematology & Oncology — Payments: $26,134
Hematology & Oncology $26,134
Dr. Liat Dagan, Md, MD
Hematology & Oncology — Payments: $9,194
Hematology & Oncology $9,194
Dr. Paul Hyman, Md, MD
Hematology & Oncology — Payments: $9,103
Hematology & Oncology $9,103
Dr. Steven Morris, M.d, M.D
Hematology & Oncology — Payments: $6,937
Hematology & Oncology $6,937
Dr. Aurea Tomeski, M.d, M.D
Hematology & Oncology — Payments: $22.15
Hematology & Oncology $22.15